ACELYRIN, Inc.: restructuring charge — ACELYRIN estimates ~$11.5M restructuring charges; cuts 40 jobs, halts izokibep in HS/PsA/AxSpa

ACELYRIN, Inc.

Workforce reduced by 40 employees (~1/3 headcount); one-time severance costs estimated at $4.3M.
Suspension of izokibep development in HS, PsA, AxSpa; focus shifts to lonigutamab for thyroid eye disease.
Cancellation of manufacturing services yields net charge of ~$7.2M ($42.9M cash expense netted with $35.7M credit voucher).
Q3 2024 restructuring charges preliminarily estimated at $3.6M severance plus full $7.2M manufacturing cancellation charge.
Credit voucher expected to offset future manufacturing costs for lonigutamab through Q1 2026.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

ACELYRIN, Inc. announced a restructuring with charges of approximately $7.2 million affecting the Company; cancellation of services under a manufacturing agreement related to suspension of new internal development of izokibep in HS, PsA and AxSpa.

Type: restructuring
Charge: approximately $7.2 million
Affected area: the Company; cancellation of services under a manufacturing agreement related to suspension of new internal development of izokibep in HS, PsA and AxSpa

Exact text from the filing

the Company now estimates that it will incur net restructuring charges of approximately $7.2 million consisting of $42.9 million of cash expense in connection with such cancellation of services netted against a $35.7 million credit voucher

View on SEC.gov

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

ACELYRIN, Inc. announced a restructuring with charges of approximately $4.3 million affecting the Company; workforce reduction connected with plan to suspend new internal investment in development of izokibep in HS, PsA and AxSpa (40 people, or approximately 1/3 of the Company’s then-existing headcount).

Type: restructuring
Charge: approximately $4.3 million
Affected area: the Company; workforce reduction connected with plan to suspend new internal investment in development of izokibep in HS, PsA and AxSpa
Headcount: 40 people, or approximately 1/3 of the Company’s then-existing headcount

Exact text from the filing

the Company now estimates that it will incur restructuring charges totaling approximately $4.3 million consisting of cash-based expenses related to one-time employee severance payments and benefits

View on SEC.gov

Browse all restructurings & charges →

Source: SEC EDGAR

accession 0001962918-24-000117

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.